Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

RPC1063

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

ozanimod

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus
Ozanimod (RPC1063) is a specific and potent small molecule modulator of the sphingosine 1-phosphate receptor 1 (S1PR1) and… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Review
2017
Review
2017
Modulation of sphingosine-1-phosphate in inflammatory bowel disease.
Inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, involve an inappropriate immune reaction in… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2016
Highly Cited
2016
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.
BACKGROUND AND PURPOSE Sphingosine1-phosphate (S1P) receptors mediate multiple events including lymphocyte trafficking, cardiac… Expand
  • figure 2
  • figure 1
  • table 1
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2016
Highly Cited
2016
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
BACKGROUND Ozanimod (RPC1063) is an oral agonist of the sphingosine-1-phosphate receptor subtypes 1 and 5 that induces peripheral… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
Review
2015
Review
2015
Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis
Sphingosine 1-phosphate (S1P) receptor modulators possess a unique mechanism of action as disease-modifying therapy for multiple… Expand
  • figure 1
  • figure 2
Is this relevant?
2015
2015
445 The TOUCHSTONE Study: A Randomized, Double-Blind, Placebo-Controlled Induction Trial of an Oral S1P Receptor Modulator (RPC1063) in Moderate to Severe Ulcerative Colitis
 
Is this relevant?
2014
2014
Pharmacokinetics and Pharmacodynamics of RPC1063 and Its Metabolites in Healthy Adult Volunteers (P1.211)
OBJECTIVE: Evaluate the clinical pharmacokinetics (PK) and pharmacodynamics (PD) of RPC1063 and its metabolites. BACKGROUND… Expand
Is this relevant?
2014
2014
Absence Of A Relevant Effect On Cardiac Repolarization In A QT/QTc (TQT) Study of RPC1063, A Novel, Selective S1P1 Receptor Agonist, In Healthy Adult Volunteers (P2.229)
Objective: Assess whether RPC1063 increases the corrected QT (QTc) interval compared to placebo (PBO). Background: RPC1063 is an… Expand
Is this relevant?
2013
2013
Safety and Tolerability of Orally Administered RPC1063, a Novel S1P1 Receptor Modulator, in Healthy Adult Volunteers, Results of a Phase 1 Study (P01.178)
OBJECTIVE: To assess safety and tolerability of oral RPC1063 as single and multiple daily doses in healthy adults. BACKGROUND… Expand
Is this relevant?
2013
2013
Metabolites of RPC1063 Contribute to In Vivo Efficacy (P05.157)
OBJECTIVE: Identify metabolites of RPC1063 and determine their activity in vitro and in vivo. BACKGROUND: RPC1063 is a potent… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE